New Funding Accelerates Commercial Launch Of HistoSonics’ Tumor-Destroying Platform

Liver cancer diagnoses are predicted to accelerate at a frightening pace in the near future, with a surge of over 50% projected to occur in the next 18 years. It’s natural, then, that a tumor-destroying platform such as Edison from startup HistoSonics would pivot to focus on attacking malignant liver tissue...